

**The Second BHD Symposium, April 22<sup>nd</sup> 2010, Washington DC, USA.**

**Researcher Session Provisional Programme**

<b>Time</b>	<b>Topic</b>	<b>Speaker</b>	<b>Joint session for Families &amp; Researchers</b>
07:30	Breakfast		✓
08:30	Registration		✓
09:00	Introduction from Dr Laura Schmidt		✓
	<b>Basic Research Session</b>	<b>Chair: Dr Laura Schmidt</b>	
09:10	A personal view of renal cancer genetics: history and lessons	Dr Berton Zbar (Invited Speaker)	✓
09:55	Understanding the cellular and molecular mechanisms of folliculin as a tumour suppressor	Dr T. Cash	
10:10	Folliculin—emerging insights into function from the crystal structure	Dr R. Nookala	
10:25	Coffee and Posters		✓
	<b>Basic Research Session</b>	<b>Chair: Dr Arnim Pause</b>	
11:05	BHD knockout in muscle causes myopathy with increased mitochondrial biogenesis	Dr H. Hasumi	
11:20	Von Hippel –Lindau tumor suppressor (VHL) regulates expression of Folliculin (FLCN) in renal clear cell carcinoma (RCC).	Dr M.F. Czyzyk-Krzeska	
11:35	Folliculin, the BHD gene product, is phosphorylated under nutrient deprivation conditions and may be a positive regulator of AMPK and mTORC1.	Dr D. Medvetz	
11:50	Folliculin is required for cell-cell contact integrity: relevance to lung cyst formation in BHD	Dr V.P. Krymskaya	
12:05	Absence of the Birt Hogg Dube' gene product is associated with increased Hypoxia Inducible Factor transcriptional activity and a Warburg effect	Dr A. Tee	
12:20	LAM and BHD, similarities and differences	Dr F. McCormack (Invited Speaker)	✓
13:05	Lunch		✓
	<b>Clinical Research Session</b>	<b>Chair: Prof. Eamonn Maher</b>	
14:05	Living with Rare Cancer - a family's perspective	Mrs J. Graff (Invited Speaker)	✓
14:35	Investigation of the Birt-Hogg-Dubé tumour suppressor gene (FLCN) in familial and sporadic colorectal cancer	Mr M. Nahorski	✓

14:50	Topical rapamycin to treat fibrofolliculomas in Birt-Hogg-Dubé syndrome	Dr L. Gijzen	✓
15:05	Diagnostic criteria, and recommendations for screening and surveillance of patients with BHDS: a North American perspective	Dr J. Toro	✓
15:20	Therapeutic targeting of the loss of the BHD suppressor gene	Dr X. Lu	✓
15:35	Evaluation and follow-up of 54 families with suspected Birt-Hogg-Dubé syndrome; a multi-center study in the Netherlands	Dr A.C. Houweling	✓
15:50	Coffee and Posters		✓
	<b>Basic Research Session</b>	<b>Chair: Dr Maurice van Steensel</b>	
16:30	Functional characterization of the FLCN tumor suppressor gene.	Dr A. Pause	
16:45	Inactivation of the FLCN tumor suppressor gene induces TFE3 activity by increasing nuclear localization	Dr S-B. Hong	
17:00	FNIP1 inactivation in vivo leads to B-cell developmental defects	Dr M. Baba	
17:15	Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2	Dr Y. Hasumi	
18:30	Dinner		✓